Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,574.00GBp
20 Feb 2019
Change (% chg)

3.40 (+0.22%)
Prev Close
1,570.60
Open
1,565.00
Day's High
1,575.40
Day's Low
1,552.00
Volume
6,494,170
Avg. Vol
8,785,070
52-wk High
1,648.80
52-wk Low
1,269.80

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.21
Market Cap(Mil.): £75,181.28
Shares Outstanding(Mil.): 4,918.63
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 38.75 30.48 33.70
EPS (TTM): 0.39 -- --
ROI: 7.58 14.95 14.45
ROE: 278.84 16.27 15.96

Mylan launches Advair generic at one-third price

Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.

12 Feb 2019

Mylan launches Advair generic at one-third price

Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.

12 Feb 2019

Mylan launches Advair generic at one-third price

Feb 12 Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.

12 Feb 2019

UPDATE 2-FTSE breaks 6-day winning streak, fire burns Ocado

* (Adds company news item, graphic, updates to closing prices)

06 Feb 2019

Profits at GSK boosted by sales of shingles vaccine

GlaxoSmithKline Plc forecast 2019 earnings above market expectations as sales of its new shingles vaccine boosted quarterly results, soothing concerns that Britain's largest drugmaker was running out of blockbuster products.

06 Feb 2019

Profits at Britain's GSK boosted by sales of shingles vaccine

GlaxoSmithKline Plc forecast 2019 earnings above market expectations as sales of its new shingles vaccine boosted quarterly results, soothing concerns that Britain's largest drugmaker was running out of blockbuster products.

06 Feb 2019

UPDATE 3-Profits at Britain's GSK boosted by sales of shingles vaccine

* GSK's drug portfolio over the years: https://tmsnrt.rs/2HWO29L (Adds analyst, CEO comments)

06 Feb 2019

Britain's GSK sees 2019 earnings hit from rival asthma treatments

Feb 6 Britain's biggest drugmaker GlaxoSmithKline Plc on Wednesday said it expects full-year adjusted profit to be hurt by new competition for its blockbuster asthma drug Advair.

06 Feb 2019

GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

FRANKFURT GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

05 Feb 2019

UPDATE 2-GSK pays up to $4.2 bln for Merck KGaA cancer immunotherapy

* M7824 to be tested against anti-cancer blockbuster Keytruda (Adds Merck exec quote, details on drug, GSK comment)

05 Feb 2019

Earnings vs. Estimates